High Hampton Holdings Corp (CSE:HC,OTCMKTS:HHPHF, FSE:OHCN)(“High Hampton” or the “Company”), a cannabis brand and distribution company in the U.S. market, today announced that it has filed its Consolidated Unaudited Financial Statements for the quarter ended February 28, 2019. The Consolidated Financial Statements and Management Discussion and Analysis are available on SEDAR at www.sedar.com.

Quarter ended February 28, 2018 Highlights:


  • The reduction in liquidity reflects the onetime acquisition costs associated with the Mojave Jane acquisition as well as the continued build out and licensing of existing assets. In January, 2019, High Hampton announced that it had been granted six new state licenses on its property in Cudahy for cultivation, distribution, manufacturing, and non-storefront retail.
  • In February 2019, High Hampton announced that CALIGOLD, its wholly owned subsidiary, had released three new products to the market that build on its award-winning brand.
  • In February 2019, High Hampton entered into a binding letter of intent to acquire 40% of the 2083 Group, a leader in California’s cannabis delivery and brand space.  When closed, the deal will provide 2083 with growth capital to expand its delivery presence and will provide High Hampton with access to 2083’s delivery customers and consumer data.
  • In February 2019, High Hampton announced the evolution of its strategy to focus on consumers and brands, consistent with the overall growth and evolution of California’s recreational and wellness-focused cannabis markets.

Subsequent to the quarter:

  • In April,2019, High Hampton announced that it had received a conditional use permit and development agreement to build out its 15,000 ft facility and distribution operations in West Sacramento.  When operational in late 2019, the facility will serve the lucrative Central and Northern California markets and serve as the company’s primary distribution hub.
  • In April,2019, High Hampton announced that demolition of its 15,000 ft facility in Cudahy had concluded and that construction was to begin in fiscal Q3, 2019.

“We concluded Q2 with additional licenses and permits to operate in both southern and northern California,” commented Gary Latham, Chief Executive Officer of High Hampton. “We also saw the addition of higher capacity extraction equipment for Mojave Jane’s operations.  That capacity buildout will conclude in Q3, 2019 and Mojave Jane will be up to operating capacity and producing roughly 100 liters of distillate monthly. The substantial ramp up of our overall business operations this year is tied to a sensible spending strategy aimed at scaling expenditures proportional to operational activity.

We are also very excited to close the loop of consumer demand to product and brand production through the investment in the 2083 Group and their delivery platform, SpeedWeed, a transaction we expect to close soon. With this addition, High Hampton will be able to fully understand the consumer markets for recreational and wellness products and produce what the markets demand.  Further, through delivery, we can then take those products and brands directly to the market.  The future looks very promising, and I am excited to begin taking products to market at scale.”

About High Hampton Holdings Corp.

High Hampton Holdings Corp. is a Canadian-based cannabis sector brand and distribution company emerging as a true vertical integrator in California’s legal cannabis space serving recreational and wellness markets. The Company’s U.S. holdings are comprised of assets set up as a vertical stack including a distribution arm through BRAVO DISTRO; branding, packaging, manufacturing & processing carried out through MOJAVE JANE and CALIGOLD; and cultivation to scale via COACHELLAGRO and 420 REALTY. Operating out of licensed strategic locations within the state, High Hampton is leveraging its brand-focused business model to generate sustainable profits delivering quality product by recognized brands.

Social Media

Facebook: facebook.com/highhampton
Twitter: twitter.com/highhamptonHC
LinkedIn: linkedin.com/HighHampton
CALIGOLD Instagram: https://www.instagram.com/caligoldofficial

Stock Exchanges

High Hampton trades in Canada, ticker symbol HC on the CSE, and in Europe, ticker symbol 0HCN on the FSE. Neither the CSE, nor the FSE has approved nor disapproved the contents of this press release. Neither the CSE, nor the FSE accepts responsibility for the adequacy or accuracy of this release.

Marijuana Industry Involvement

Canadian listings (CSE) will remain in good standing as long as they provide the disclosure that is rightly required by regulators and complying with applicable licensing requirements and the regulatory framework enacted by the applicable state in which they operate. Marijuana is legal in certain states however marijuana remains illegal under US federal law and the approach to enforcement of US federal law against marijuana is subject to change. Shareholders and investors need to be aware that adverse enforcement actions could affect their investments and that High Hampton’s ability to access private and public capital could be affected and or could not be available to support continuing operations.

On behalf of the Board of Directors

High Hampton Holdings Corp.

Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In particular, this release contains forward-looking information relating to the intention of the parties to complete the Acquisition and certain ancillary transactions contemplated thereby. These transactions are subject to a number of material risks, and there is no assurance that they will be completed on the terms or within the timeframes currently contemplated, or at all. The forward-looking information contained in this press release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.

All monetary references herein refer to Canadian dollars unless otherwise specified.

For further information: 8 Wellington St. E. Mezzanine Level | Toronto, On | M5E 1C5 | www.HighHampton.com; Gary Latham, Chief Executive Officer & Director, Email: glatham@highhampton.com, Phone: 703.629.5338; Christian Scovenna, Senior VP Corporate Finance, Email: christian@HighHampton.com, Phone: 416.453.4708

Click here to connect with High Hampton Holdings Corp (CSE:HC,OTCMKTS:HHPHF, FSE:OHCN) for an Investor Presentation. 

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less